CBD Unlimited Applauds the Commencement of Clinical Trials on CBD’s Potential Role in Slowing COVID-19

Cave Creek, AZ, May 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Endexx Corporation, (OTC: EDXC) (the “Company” or a/k/a “CBD Unlimited”), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products, today announced it is supportive of the recent research conducted with regard to the anti-inflammatory capabilities of cannabis compounds and its potential role in the fight against the coronavirus.

CBD Unlimited specifically applauds the research analyses and clinical trials conducted in Israel. In an article recently published in Benzinga, Israeli researchers have launched three clinical trials that evaluate the safety and activity of utilizing CBD's anti-inflammatory properties as a potential COVID-19 treatment.

The in-human trials will allow scientists and researchers to monitor the therapeutic effect that CBD may have in combination with another treatment on hospitalized patients with COVID-19 infections. The researchers leading the study will investigate whether CBD’s anti-inflammatory properties could lower respiratory symptoms experienced in moderate COVID-19 patients.

Canadian researchers have also announced intentions to study what role cannabis might play in slowing COVID-19. The linked articles below demonstrate various beliefs in cannabis’ anti-inflammatory properties and the possibility of playing a crucial role in potential treatment.

●      Israel Researchers Launch Clinical Trials To Test CBD As COVID-19 Treatment Supplement

●      Could cannabis terpene formulation treat COVID-19?

●      Cannabis Regulators Respond to Coronavirus Concerns

"We are proud to be part of a community of innovators that are always looking for ways to contribute their knowledge to a greater cause, especially under these circumstances. Understanding the science behind cannabidiol extraction is what helped build CBD Unlimited. To see what our colleagues and industry peers are able to do with the compounds related to CBD are terrific," commented CEO and Chairman of Endexx, Todd Davis. “There is more research to be conducted, and we look forward to seeing the outcome of these clinical trials,” continued Davis.